LINC02343: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02343

NCBI ID: G105370158

LINC02343

Other Name(s): long intergenic non-protein coding RNA 2343 | LOC105370158 variant X1 | Uncharacterized LOC105370158, transcript variant X1

LINC02343: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02343 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its unique structure, which consists of a series of alternating intron-exon regions separated by short non-coding regions (NCRs). LINC02343 has been shown to play a critical role in various cellular processes, including cell adhesion, migration, and tissue repair.

Drug Target Potential

The drug targeting potential of LINC02343 is due to its unique structure and various functions that have been identified in cell culture and animal models. One of the key factors that make LINC02343 an attractive drug target is its ability to interact with various signaling pathways, including the NF-kappa pathway.

The NF-kappa pathway is a well-established signaling pathway that plays a crucial role in cellular processes such as cell growth, differentiation, and inflammation. LINC02343 has been shown to regulate the activity of the NF-kappa pathway by interacting with its downstream target, SMAD2. This interaction between LINC02343 and SMAD2 highlights the potential of LINC02343 as a drug target for NF-kappa-related diseases.

In addition to its interaction with SMAD2, LINC02343 has also been shown to interact with other signaling pathways, including the PI3K/Akt pathway. This interaction between LINC02343 and PI3K/Akt suggests that LINC02343 may also be a potential drug target for diseases associated with PI3K/Akt signaling pathway dysfunction.

Biomarker Potential

The diagnostic potential of LINC02343 is due to its unique expression patterns in various biological samples, including human tissues and fluids. One of the key biomarkers associated with LINC02343 is its expression level, which has been shown to vary depending on the specific disease state.

For example, LINC02343 has been shown to be expressed at higher levels in cancer tissues compared to normal tissues. This increased expression of LINC02343 in cancer tissues may serve as a potential biomarker for cancer diagnosis and monitoring.

Another example is the regulation of LINC02343 by the microRNA (miRNA) pathway. LINC02343 has been shown to be regulated by miRNA-30a, which is a well-established regulator of the miRNA pathway. The regulation of LINC02343 by miRNA-30a suggests that LINC02343 may also be a potential biomarker for diseases associated with miRNA function gone awry.

Conclusion

In conclusion, LINC02343 is a long non-coding RNA that has unique structure and functions. Its ability to interact with various signaling pathways, including the NF-kappa and PI3K/Akt pathways, makes it an attractive drug target for NF-kappa- and PI3K/Akt-related diseases. Its unique expression patterns in various biological samples also suggest that it may be a potential biomarker for cancer and other diseases. Further research is needed to fully understand the potential of LINC02343 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2343

The "LINC02343 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02343 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets